chemotherapy induced neuropathy. Polyneuropathy in neoplastic disease
Conditions
Interventions
Intervention 1: Intervention group: Patients receive melatonin (weight less than 40 kg: 3 mg, weight more than 40 kg: 5 mg) for 30 days 4 hours before bedtime and after dinner. Intervention 2: Control
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: Age: 6-12 years old Patients with ALL Incidence of neuropathy following receiving vincristine
Exclusion criteria
Exclusion criteria: Hypersensitivity to melatonin Patients over 12 years of age CNS tumor (except meduloblastoma), focal neurological symptoms, CN metastasis Other neuromuscular disorders (traumatic brain injury, cerebral palsy) Recurrent diseases Unstable hemodynamic status Amputation of upper and lower limbs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropathy. Timepoint: The second and fourth weeks after starting treatment. Method of measurement: ped-mTNS and PCIN questionnaires. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: The second and fourth weeks after starting treatment. Method of measurement: Peds QL Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactToktam Faghihi
Tehran University of Medical Sciences
Outcome results
None listed